Locally Advanced Solid Tumor

46 clinical trials · Condition

Record	Firm	Date
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (NCT05384626)	Nuvalent Inc.	2022-06-09
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma (NCT05218148)	Aiping Zhou	2022-04-01
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors (NCT05275478)	Tango Therapeutics, Inc.	2022-03-23
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (NCT05169437)	Tempus AI	2022-03-15
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (NCT05081609)	Ascendis Pharma Oncology Division A/S	2022-01-11
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) (NCT05118789)	Nuvalent Inc.	2022-01-04
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (NCT04914117)	RemeGen Co., Ltd.	2021-11-29
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (NCT04975958)	Adlai Nortye Biopharma Co., Ltd.	2021-09-07
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (NCT05002140)	XRad Therapeutics Inc	2021-08-24
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (NCT04799054)	Ascendis Pharma Oncology Division A/S	2021-03-18
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib (NCT04814667)	Centre Leon Berard	2021-02-23
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors (NCT04614740)	Jiangsu vcare pharmaceutical technology co., LTD	2020-11-20
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib (NCT04770688)	Shanghai Chest Hospital	2020-11-19
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors (NCT04383210)	Elevation Oncology	2020-09-29
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802)	Ocellaris Pharma, Inc.	2020-09-24
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963)	Ikena Oncology	2019-12-18
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors (NCT04084366)	OBI Pharma, Inc	2019-11-25
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer (NCT04250948)	Sun Yat-sen University	2019-10-12
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (NCT04050709)	ImmunityBio, Inc.	2019-07-18
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488)	Compass Therapeutics	2019-05-17
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03284502)	Hanmi Pharmaceutical Company Limited	2017-05-22
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT01390818)	EMD Serono	2011-05-01

Track Locally Advanced Solid Tumor automatically

Every clearance here is in the API, with alerts when new ones post.